6 ways PBMs influence the drug market

Pharmacy benefit manufacturers complicate the drug pricing system and drive up out-of-pocket costs for patients, according to a new report from Pacific Research Institute.

Advertisement

For the report, the Pacific Research Institute reviewed existing literature surrounding the role of PBMs and their impact on the U.S. pharmaceutical market.

Here are six ways PBMs affect the drug market, according to Pacific Research Institute.

1. PBMs create pricing uncertainty by incentivizing higher list prices for drugs that allow for large rebates and discounts.

2. This large discrepancy between list prices and transaction prices results in higher patient copays than necessary.

3. Higher list prices and copays may push Medicare Part D patients into the coverage gap faster.

4. PBMs enact costly — and often unknown — fees, which leads to substantial revenue uncertainty and volatility for pharmacies.

5. PBMs also increase their share of gross expenditures at the expense of pharmacies and manufacturers.

6. By controlling drug formularies, PBMs hold too much influence on the treatments patients can access.

More articles on supply chain:

Pharma websites prioritize ads over education, physicians say
Trump administration seeks to tackle high drug costs — without Congress
WHO calls for global drug price transparency

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.